Abstract:Key PointsMuscle wasting is a debilitating condition that develops with ageing and more rapidly with inactivity (bed rest) and in various systemic diseases (for example, cancer, renal failure, chronic obstructive pulmonary disease, sepsis, HIV and trauma). Fibre atrophy primarily results from an acceleration of protein degradation, often combined with reduced protein synthesis. Treatments that prevent this activation of proteolysis or increase protein synthesis offer considerable promise to combat this debilitating process.Various types of rapid muscle wasting develop through a common transcriptional programme involving the induction of a set of atrophy-related genes (atrogenes) by forkhead box protein O (FOXO) transcription factors and reduced signalling by the PI3K–AKT–mTOR pathway.The resulting muscle weakness is a consequence of the degradation of myofibrils, which is catalysed by ubiquitin ligases that target different components of the contractile apparatus for proteasomal degradation. By contrast, the loss of endurance results from the breakdown of mitochondria via autophagy.Myostatin, an autocrine inhibitor of normal muscle growth, and its circulating homologue activin A, also trigger muscle protein loss in various catabolic states via the activation of SMAD2 and SMAD3, which function together with FOXO transcription factors.Antibodies against myostatin or activin A, or agents that block their receptor — activin A receptor, type IIB (ActRIIB) — in muscle could be a promising approach to combat muscle loss caused by cancer-associated cachexia, renal failure and ageing. Indeed, these treatments helped to preserve muscle and prolong longevity in tumour-bearing mice, and several of these treatments are currently in clinical trials.Glucocorticoids and various circulating inflammatory mediators, such as tumour necrosis factor-α (TNFα) and interleukin-6 (IL-6), have also been implicated in excessive muscle proteolysis in cachexia, but their roles in different catabolic states remain uncertain and controversial.Recent studies have increased our understanding of the biochemical mechanisms of atrophy and have identified many intracellular proteins that are crucial in muscle wasting (for example, SMADs, tripartate motif-containing protein 32 (TRIM32), nuclear factor-κB (NF-κB)) or that combat this process (for example, peroxisome proliferator-activated receptor-γ coactivator 1α (PGC1α), sirtuin1 (SIRT1) and JUNB). Their manipulation by small molecules offers many opportunities for the rational design of new treatments for this condition.

The clinical relevance and mechanism of skeletal muscle wasting

Muscle wasting in disease: molecular mechanisms and promising therapies

Skeletal muscle atrophy: From mechanisms to treatments

Muscle wasting in cancer

Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training

Muscle wasting in ageing and chronic illness

Nutritional Strategies for Muscle Atrophy: Current Evidence and Underlying Mechanisms

Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs

Deliberation on debilitating condition of cancer cachexia: Skeletal muscle wasting

Mechanisms underlying the anti-wasting effect of l-carnitine supplementation under pathologic conditions: evidence from experimental and clinical studies

Emerging Strategies Targeting Catabolic Muscle Stress Relief

Molecular Mechanisms Underlying Intensive Care Unit-Acquired Weakness and Sarcopenia

Muscle Wasting Diseases: Novel Targets and Treatments

Molecular mechanisms of cancer cachexia‐induced muscle atrophy (Review)

Molecular mechanisms of cancer cachexia-related loss of skeletal muscle mass: data analysis from preclinical and clinical studies

The role of extracellular vesicles in skeletal muscle wasting

Micro(RNA)-managing muscle wasting

A narrative review of skeletal muscle atrophy in critically ill children: pathogenesis and chronic sequelae

Cancer cachexia: molecular mechanisms and treatment strategies

Modulating Metabolism to Improve Cancer-Induced Muscle Wasting

Novel molecular targets of muscle wasting in cancer patients